Covid-19. Vaccine maker BioNTech expects return to normal in a year

The CEO of the German company BioNTech, which developed with Pfizer a vaccine against the new coronavirus, spoke on Sunday of a possible return to normal by next winter.

On the BBC, Professor Ugur Sahin estimated “Absolutely essential” to have a high rate of vaccination before fall 2021.

“If everything continues to go well, we will start delivering the vaccine at the end of this year”, did he declare. “Our goal is to deliver over 300 million doses of vaccine through April next year, which would allow us to start making an impact.” against the virus, which has killed more than 1.3 million people worldwide.

Several vaccines in phase 3

“The biggest impact will take place until the summer. Summer will help us anyway because the infection rate will drop ”, he continued. “What is absolutely essential is that we have a high vaccination rate before fall / winter next year”.

“I am confident it will happen” because many vaccine manufacturers have been asked to increase production, he said, adding: “We could have a normal winter next year”.

According to Pfizer and BioNTech, their vaccine is “90% effective” against Covid-19, according to the large-scale phase 3 trial still underway, last step before an application for approval. Several other vaccines are also at this stage of research, suggesting the horizon of a return to normal.


Leave a Comment